710 related articles for article (PubMed ID: 35870791)
21. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
[TBL] [Abstract][Full Text] [Related]
22. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
[TBL] [Abstract][Full Text] [Related]
23. Factors Associated with Change in SARS-CoV-2 Antibody Titers from Three to Six Months after the Administration of the BNT162b2 mRNA COVID-19 Vaccine among Healthcare Workers in Japan: A Prospective Study.
Mochizuki T; Hori T; Yano K; Ikari K; Okazaki K
Intern Med; 2022 Apr; 61(8):1139-1143. PubMed ID: 35185050
[TBL] [Abstract][Full Text] [Related]
24. Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers.
Kwon SR; Kim N; Park H; Minn D; Park S; Roh EY; Yoon JH; Shin S
J Korean Med Sci; 2022 May; 37(19):e135. PubMed ID: 35578582
[TBL] [Abstract][Full Text] [Related]
25. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents.
Chong Y; Goto T; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K
Influenza Other Respir Viruses; 2022 Nov; 16(6):1066-1071. PubMed ID: 35962568
[TBL] [Abstract][Full Text] [Related]
26. An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status.
Lumley SF; Rodger G; Constantinides B; Sanderson N; Chau KK; Street TL; O'Donnell D; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Stoesser NE; Matthews PC; Jeffery K; Eyre DW;
Clin Infect Dis; 2022 Apr; 74(7):1208-1219. PubMed ID: 34216472
[TBL] [Abstract][Full Text] [Related]
27. Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers.
Tamura M; Fujita R; Sato T; Sato R; Kato Y; Nagasawa M; Matsumoto T
J Infect Chemother; 2022 Nov; 28(11):1478-1482. PubMed ID: 35921965
[TBL] [Abstract][Full Text] [Related]
28. Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan.
Sanada T; Honda T; Higa M; Yamaji K; Yasui F; Kohara M
J Infect Chemother; 2023 Mar; 29(3):339-346. PubMed ID: 36584813
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
[TBL] [Abstract][Full Text] [Related]
30. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
[TBL] [Abstract][Full Text] [Related]
31. Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020-2022): A retrospective longitudinal SARS-CoV-2 serological surveillance.
De Pace V; Bruzzone B; Ricucci V; Calcavecchia N; Guarona G; Giberti I; Costa E; Ogliastro M; Galano B; Nigro N; Murgia D; Nanni L; Orsi A
Hum Vaccin Immunother; 2023 Aug; 19(2):2258632. PubMed ID: 37724517
[TBL] [Abstract][Full Text] [Related]
32. Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination.
Cimas FJ; Torres J; Ontañón J; de Cabo C; Lozano J; Requena MÁ; Blas J; Rodríguez-García JL; Mas A; Solera J
Front Immunol; 2023; 14():1097747. PubMed ID: 36776854
[TBL] [Abstract][Full Text] [Related]
33. Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff.
Uwamino Y; Kurafuji T; Sato Y; Tomita Y; Shibata A; Tanabe A; Yatabe Y; Noguchi M; Arai T; Ohno A; Yokota H; Yamasawa W; Uno S; Nishimura T; Hasegawa N; Saya H; Wakui M; Murata M;
Vaccine; 2022 Feb; 40(7):1019-1025. PubMed ID: 35033389
[TBL] [Abstract][Full Text] [Related]
34. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.
Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD
Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279
[TBL] [Abstract][Full Text] [Related]
35. Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021-2022.
Perrig L; Abela IA; Banholzer N; Audigé A; Epp S; Mugglin C; Zürcher K; Egger M; Trkola A; Fenner L
Swiss Med Wkly; 2023 Dec; 153():3502. PubMed ID: 38579325
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
Kanai D; Wakui H; Haze T; Azushima K; Kinguchi S; Tsukamoto S; Kanaoka T; Urate S; Toya Y; Hirawa N; Kato H; Watanabe F; Hanaoka K; Hanaoka M; Mitsuhashi H; Yamaguchi S; Ohnishi T; Tamura K
Clin Exp Nephrol; 2022 Oct; 26(10):988-996. PubMed ID: 35751753
[TBL] [Abstract][Full Text] [Related]
37. Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.
Vietri MT; D'Elia G; Caliendo G; Passariello L; Albanese L; Molinari AM; Angelillo IF
Vaccine; 2022 Sep; 40(39):5726-5731. PubMed ID: 36041940
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.
Franzese M; Coppola L; Silva R; Santini SA; Cinquanta L; Ottomano C; Salvatore M; Incoronato M
Front Immunol; 2022; 13():947187. PubMed ID: 36248864
[TBL] [Abstract][Full Text] [Related]
39. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
Viruses; 2022 May; 14(5):. PubMed ID: 35632698
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
